Bristol Myers Squibb and 2seventy bio, Inc.announced positive topline results from KarMMa-3, a Phase 3, global, randomized, multicenter, open-label study evaluating Abecma (idecabtagene vicleucel) compared to standard combination regimens in adults with multiple myeloma that is relapsed and refractory after two to four prior lines of therapy and refractory to the last regimen. KarMMa-3 is […]
The post Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma first appeared on World Pharma Today.This post first appeared on Leading Pharmaceutical Industry Online Platform, please read the originial post: here